ClinicalTrials.gg
CompletedNCT03843632Updated Apr 6, 2021Results posted

Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)

A Phase 3 interventional study of VARIVAX™ in Varicella, sponsored by Merck Sharp & Dohme LLC. Completed at 5 sites in Russian Federation. Open to participants aged 12 Months to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
12 Months to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.

Enrollment
25th of 36
150 · median 404
Started
2019
the only one that year
Phase 3
12 of 36
2 open now
Registered
24th of 36
by date
Lead sponsor
5 of 36
Merck Sharp & Dohme LLC

Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 25th largest by enrollment, is the only one that started in 2019, is one of 12 in phase 3, and was the 24th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 12 Months to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Chickenpox Vaccine in Chickenpox, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the immunogenicity and safety of VARIVAX™ vaccine in healthy Russian children, adolescents, and adults. No formal hypothesis was tested.

03

Conditions studied

  • Varicella

Browse trials for

04

Who can participate

Ages eligible
12 Months to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • has a negative clinical history for varicella and herpes zoster
  • females of have a negative pregnancy test prior to each study vaccination
  • females of reproductive potential remain abstinent or use 2 acceptable methods of during study until 3 months following last study vaccination
  • females not of reproductive potential do not require a pregnancy test or use of contraceptives
  • legal representative of adult or parent of children understands risks involved with, consent to participate in, and comply with the study procedures

Exclusion criteria

Exclusion Criteria:

  • has a history of allergy or anaphylactic reaction to neomycin, gelatin, or any component of VARIVAX\^TM
  • has received any form of varicella or herpes zoster vaccine at any time prior to study, or anticipates receiving any during study
  • has received immune globulin, a blood transfusion or blood derived products within prior 5 months or plans to do so during study
  • has received aspirin or any aspirin-containing products within prior 14 days
  • has been exposed to varicella or herpes zoster in the prior 4 weeks involving playmate, hospital or continuous household contact, or had contact with a newborn whose mother had chickenpox 5 days before or 2 days after delivery
  • has, or lives with a person who has, any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity including those resulting from use or other therapy
  • has received glucocorticosteroids for more than 5 consecutive days within prior 3 months, or any dose of glucocorticoids within prior 7 days, or expects to use glucocorticosteroids during the study
  • was vaccinated with licensed non-live or within prior 30 days or expects vaccination during 42 day follow-up postvaccination period
  • had a fever within 72 hours prior to study vaccination
  • has participated in another trial within prior 30 days, is currently participating in another trial, or plans to participate in another trial during the planned study period for this trial
  • is pregnant or nursing
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    VARIVAX™

    All participants will receive one dose subcutaneous (SC) VARIVAX™ on Day 1. Adult participants and adolescent participants 13 years and older will also receive a second SC dose VARIVAX™ on Day 43.

    Biological: VARIVAX™

Interventions

  • BiologicalVARIVAX™

    VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).

06

What researchers measure

Primary outcomes

  1. Varicella Zoster Virus (VZV) Antibody Response Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline

    VZV antibody titers were measured using a glycoprotein enzyme-linked immunosorbent assay (gpELISA). The VZV antibody response rate was defined as the percentage of participants with a post-vaccination VZV antibody titer ≥5 gpELISA units/mL for participants whose baseline VZV antibody titer was \<1.25 gpELISA units/mL. VZV antibody response rate was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.

    Time frame: Adults and Adolescents: 6 weeks post Vaccination 2 (up to approximately 86 days), Children: 6 weeks post Vaccination 1 (up to approximately 43 days)

  2. Geometric Mean Titers (GMTs) of VZV Antibodies at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline

    GMTs of VZV antibodies were measured post-vaccination using a gpELISA. GMT was calculated at each time point by taking the log of the titers, averaging over all participants values, and then back-transforming to the original scale. GMT was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.

    Time frame: Adults and Adolescents: 6 weeks post Vaccination 2 (up to approximately 86 days), Children: 6 weeks post Vaccination 1 (up to approximately 43 days)

  3. VZV Antibody Seroconversion Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline

    VZV antibody levels were measured using a gpELISA. The VZW antibody seroconversion rate was defined as the percentage of participants with VZV antibodies ≥1.25 gpELISA units/mL in participants with a baseline VZV antibody titer \<1.25 gpELISA units/mL. VZW antibody seroconversion was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.

    Time frame: Adults and Adolescents: 6 weeks post Vaccination 2 (up to approximately 86 days), Children: 6 weeks post Vaccination 1 (up to approximately 43 days)

  4. GMTs of VZV Antibodies at Day 1 and 6 Weeks Post Last Vaccination in Participants Who Were Seropositive at Baseline

    GMTs of VZV antibodies were measured post-vaccination using a gpELISA. GMT was calculated at each time point by taking the log of the titers, averaging over all participants values, and then back-transforming to the original scale. GMT was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seropositive to VZW at baseline. Per protocol, confidence intervals (CIs) were only calculated when there were at least 5 participants who were seropositive in a treatment group.

    Time frame: Day 1 (Baseline), 6 weeks post last vaccination (Day 43 for children and Day 84 for adults and adolescents)

  5. Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination in Participants Who Were Seropositive at Baseline

    GMTs were measured using a gpELISA. For participants who were seropositive at baseline (baseline VZV antibody titer ≥1.25 gpELISA units/mL), the GMFR was calculated as the ratio of the VZV GMT at 6 weeks post last vaccination to the VZV GMT at Day 1 (baseline). The GMFR from Day 1 was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seropositive to VZW at baseline. Per protocol, CIs were only calculated when there were at least 5 participants who were seropositive in a treatment group.

    Time frame: Day 1 (Baseline), 6 weeks post last vaccination (Day 43 for children and Day 84 for adults and adolescents)

  6. Percentage of Participants With ≥4-Fold Rise in Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination Among Participants Who Were Seropositive at Baseline

    GMTs were measured using a gpELISA. For participants who were seropositive at baseline (baseline VZV antibody titer ≥1.25 gpELISA units/mL), the percentage of participants with a ≥4-fold rise in VZV antibody titer from Day 1 (baseline) to post-vaccination was assessed and reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents). Per protocol, CIs were only calculated when there were at least 5 participants who were seropositive in a treatment group.

    Time frame: Day 1 (Baseline), 6 weeks post last vaccination (Day 43 for children and Day 84 for adults and adolescents)

Secondary outcomes

  1. Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) Post-Vaccination 1

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs, which included erythema, pain, and swelling, were recorded on a Vaccine Report Card (VRC). The percentage of participants who experienced solicited injection-site AEs after Vaccination 1 (up to approximately 5 days post-vaccination) was summarized for all study arms.

    Time frame: Up to approximately 5 days post-Vaccination 1

  2. Percentage of Participants With Solicited Injection-Site AEs Post-Vaccination 2

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs, which included erythema, pain, and swelling, were recorded on a VRC. The percentage of participants who experienced solicited injection-site AEs after Vaccination 2 (up to approximately 5 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).

    Time frame: Up to approximately 5 days post-Vaccination 2 (up to approximately 48 days)

  3. Percentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 1

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Unsolicited injection-site AEs were recorded on a VRC. The percentage of participants who experienced unsolicited injection-site AEs after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.

    Time frame: Up to approximately 42 days post-Vaccination 1

  4. Percentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 2

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Unsolicited injection-site AEs were recorded on a VRC. The percentage of participants who experienced unsolicited injection-site AEs after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).

    Time frame: Up to approximately 42 days post-Vaccination 2 (up to approximately 86 days)

  5. Percentage of Participants With Elevated Temperature Post-Vaccination 1

    The participant's temperature was taken in the evening after Vaccination 1 and daily through Day 28, and was recorded on a VRC. An elevated temperature was defined as ≥39.0 °C (102.2 °F). The percentage of participants with elevated temperature after Vaccination 1 (up to approximately 28 days post-vaccination) was summarized for all study arms.

    Time frame: Up to 28 days post-Vaccination 1

  6. Percentage of Participants With Elevated Temperature Post-Vaccination 2

    The participant's temperature was taken in the evening after Vaccination 2 and daily through Day 28, and was recorded on a VRC. An elevated temperature was defined as ≥39.0 °C (102.2 °F). The percentage of participants with elevated temperature after Vaccination 2 (up to approximately 28 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).

    Time frame: Up to 28 days post-Vaccination 2 (up to approximately 71 days)

  7. Percentage of Participants With Varicella- and Herpes Zoster-Like Rashes Post-Vaccination 1

    The development of varicella-like and herpes zoster-like rashes was recorded on a VRC. The percentage of participants who experienced varicella-like and herpes zoster-like rashes after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.

    Time frame: Up to approximately 42 days post-Vaccination 1

  8. Percentage of Participants With Varicella- and Herpes Zoster-Like Rashes Post-Vaccination 2

    The development of varicella-like and herpes zoster-like rashes was recorded on a VRC. The percentage of participants who experienced varicella-like and herpes zoster-like rashes after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).

    Time frame: Up to approximately 42 days post-Vaccination 2 (up to approximately 86 days)

  9. Percentage of Participants With Systemic AEs Post-Vaccination 1

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A systemic AE was defined as any non-injection-site AE. Systemic AEs were recorded on a VRC. The percentage of participants who experienced a systemic AE after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.

    Time frame: Up to approximately 42 days post-Vaccination 1

  10. Percentage of Participants With Systemic AEs Post-Vaccination 2

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A systemic AE was defined as any non-injection-site AE. Systemic AEs were recorded on a VRC. The percentage of participants who experienced a systemic AE after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).

    Time frame: Up to approximately 42 days post-Vaccination 2 (up to approximately 86 days)

  11. Percentage of Participants With 1 or More Serious Adverse Events (SAEs) Post-Vaccination 1 or Post-Vaccination 2

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event. The percentage of participants who experienced one or more SAEs after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.

    Time frame: Up to 42 days post-Vaccination 1 or post-Vaccination 2 (up to approximately 86 days)

  12. Percentage of Participants With Vaccine-Related SAEs Post-Vaccination 1 or Post-Vaccination 2

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A vaccine-related SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event, that was considered at least possibly related to the study vaccine. The percentage of participants who experienced one or more vaccine-related SAEs after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.

    Time frame: Up to 42 days post-Vaccination 1 or post-Vaccination 2 (up to approximately 86 days)

  13. Percentage of Participants With Vaccine-Related Death Post-Vaccination 1 or Post-Vaccination 2

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A vaccine-related SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event, that was considered at least possibly related to the study vaccine. The percentage of participants who experienced a vaccine-related SAE that resulted in death after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.

    Time frame: Up to 42 days post-Vaccination 1 or post-Vaccination 2 (up to approximately 86 days)

07

Results

Posted Apr 6, 2021

Participant flow

This study enrolled healthy Russians aged 12 months and older. Additional inclusion criteria applied.

Participant flow — Overall Study
MilestoneVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Started50303337
Vaccination 150303337
Vaccination 2493000
Completed49303337
Not completed1000
Withdrew: Withdrawal by subject1000

Outcome measures

PrimaryVaricella Zoster Virus (VZV) Antibody Response Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline

VZV antibody titers were measured using a glycoprotein enzyme-linked immunosorbent assay (gpELISA). The VZV antibody response rate was defined as the percentage of participants with a post-vaccination VZV antibody titer ≥5 gpELISA units/mL for participants whose baseline VZV antibody titer was \<1.25 gpELISA units/mL. VZV antibody response rate was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.

Time frame:
Adults and Adolescents: 6 weeks post Vaccination 2 (up to approximately 86 days), Children: 6 weeks post Vaccination 1 (up to approximately 43 days)
Reported as:
Number · Percentage of participants
Varicella Zoster Virus (VZV) Antibody Response Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Varicella Zoster Virus (VZV) Antibody Response Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline100.0 (86.8 to 100.0)100.0 (81.5 to 100.0)95.5 (77.2 to 99.9)100.0 (89.7 to 100.0)
PrimaryGeometric Mean Titers (GMTs) of VZV Antibodies at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline

GMTs of VZV antibodies were measured post-vaccination using a gpELISA. GMT was calculated at each time point by taking the log of the titers, averaging over all participants values, and then back-transforming to the original scale. GMT was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.

Time frame:
Adults and Adolescents: 6 weeks post Vaccination 2 (up to approximately 86 days), Children: 6 weeks post Vaccination 1 (up to approximately 43 days)
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Titers (GMTs) of VZV Antibodies at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline
gpELISA units/mLVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Geometric Mean Titers (GMTs) of VZV Antibodies at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline70.7 ± 47.978.6 ± 46.511.3 ± 7.313.9 ± 11.2
PrimaryVZV Antibody Seroconversion Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline

VZV antibody levels were measured using a gpELISA. The VZW antibody seroconversion rate was defined as the percentage of participants with VZV antibodies ≥1.25 gpELISA units/mL in participants with a baseline VZV antibody titer \<1.25 gpELISA units/mL. VZW antibody seroconversion was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seronegative to VZW at baseline.

Time frame:
Adults and Adolescents: 6 weeks post Vaccination 2 (up to approximately 86 days), Children: 6 weeks post Vaccination 1 (up to approximately 43 days)
Reported as:
Number · Percentage of participants
VZV Antibody Seroconversion Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
VZV Antibody Seroconversion Rate at 6 Weeks Post Last Vaccination in Participants Who Were Seronegative at Baseline100.0 ± 86.8100.0 ± 81.595.5 ± 77.2100.0 ± 89.7
PrimaryGMTs of VZV Antibodies at Day 1 and 6 Weeks Post Last Vaccination in Participants Who Were Seropositive at Baseline

GMTs of VZV antibodies were measured post-vaccination using a gpELISA. GMT was calculated at each time point by taking the log of the titers, averaging over all participants values, and then back-transforming to the original scale. GMT was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seropositive to VZW at baseline. Per protocol, confidence intervals (CIs) were only calculated when there were at least 5 participants who were seropositive in a treatment group.

Time frame:
Day 1 (Baseline), 6 weeks post last vaccination (Day 43 for children and Day 84 for adults and adolescents)
Reported as:
Geometric mean · gpELISA units/mL
GMTs of VZV Antibodies at Day 1 and 6 Weeks Post Last Vaccination in Participants Who Were Seropositive at Baseline
gpELISA units/mLVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Day 1 (Baseline)71.1 (31.4 to 161.2)13.4 (5.8 to 31.0)24.8 (7.2 to 85.5)4.2 (NA to NA)
Post Last Vaccination216.7 (132.8 to 353.6)151.7 (92.5 to 248.6)125.0 (37.9 to 411.7)47.6 (NA to NA)
PrimaryGeometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination in Participants Who Were Seropositive at Baseline

GMTs were measured using a gpELISA. For participants who were seropositive at baseline (baseline VZV antibody titer ≥1.25 gpELISA units/mL), the GMFR was calculated as the ratio of the VZV GMT at 6 weeks post last vaccination to the VZV GMT at Day 1 (baseline). The GMFR from Day 1 was reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents) for participants who were seropositive to VZW at baseline. Per protocol, CIs were only calculated when there were at least 5 participants who were seropositive in a treatment group.

Time frame:
Day 1 (Baseline), 6 weeks post last vaccination (Day 43 for children and Day 84 for adults and adolescents)
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination in Participants Who Were Seropositive at Baseline
RatioVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination in Participants Who Were Seropositive at Baseline3.0 (2.0 to 4.8)11.3 (4.6 to 27.5)5.0 (2.6 to 9.7)11.2 (NA to NA)
PrimaryPercentage of Participants With ≥4-Fold Rise in Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination Among Participants Who Were Seropositive at Baseline

GMTs were measured using a gpELISA. For participants who were seropositive at baseline (baseline VZV antibody titer ≥1.25 gpELISA units/mL), the percentage of participants with a ≥4-fold rise in VZV antibody titer from Day 1 (baseline) to post-vaccination was assessed and reported for all study arms at 6 weeks post last vaccination (Vaccination 1 for children and Vaccination 2 for adults and adolescents). Per protocol, CIs were only calculated when there were at least 5 participants who were seropositive in a treatment group.

Time frame:
Day 1 (Baseline), 6 weeks post last vaccination (Day 43 for children and Day 84 for adults and adolescents)
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥4-Fold Rise in Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination Among Participants Who Were Seropositive at Baseline
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Percentage of Participants With ≥4-Fold Rise in Antibody Titers From Day 1 to 6 Weeks Post Last Vaccination Among Participants Who Were Seropositive at Baseline60.9 (38.5 to 80.3)66.7 (34.9 to 90.1)54.5 (23.4 to 83.3)100.0 (NA to NA)
SecondaryPercentage of Participants With Solicited Injection-Site Adverse Events (AEs) Post-Vaccination 1

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs, which included erythema, pain, and swelling, were recorded on a Vaccine Report Card (VRC). The percentage of participants who experienced solicited injection-site AEs after Vaccination 1 (up to approximately 5 days post-vaccination) was summarized for all study arms.

Time frame:
Up to approximately 5 days post-Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) Post-Vaccination 1
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Injection-site erythema16.03.33.00.0
Injection-site pain40.023.330.313.5
Injection-site swelling10.00.03.00.0
SecondaryPercentage of Participants With Solicited Injection-Site AEs Post-Vaccination 2

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs, which included erythema, pain, and swelling, were recorded on a VRC. The percentage of participants who experienced solicited injection-site AEs after Vaccination 2 (up to approximately 5 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).

Time frame:
Up to approximately 5 days post-Vaccination 2 (up to approximately 48 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Solicited Injection-Site AEs Post-Vaccination 2
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Injection-site erythema18.40——
Injection-site pain49.023.3——
Injection-site swelling8.23.3——
SecondaryPercentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 1

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Unsolicited injection-site AEs were recorded on a VRC. The percentage of participants who experienced unsolicited injection-site AEs after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.

Time frame:
Up to approximately 42 days post-Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 1
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Percentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 12.03.30.05.4
SecondaryPercentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 2

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Unsolicited injection-site AEs were recorded on a VRC. The percentage of participants who experienced unsolicited injection-site AEs after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).

Time frame:
Up to approximately 42 days post-Vaccination 2 (up to approximately 86 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 2
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Percentage of Participants With Unsolicited Injection-Site AEs Post-Vaccination 20.00.0——
SecondaryPercentage of Participants With Elevated Temperature Post-Vaccination 1

The participant's temperature was taken in the evening after Vaccination 1 and daily through Day 28, and was recorded on a VRC. An elevated temperature was defined as ≥39.0 °C (102.2 °F). The percentage of participants with elevated temperature after Vaccination 1 (up to approximately 28 days post-vaccination) was summarized for all study arms.

Time frame:
Up to 28 days post-Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Elevated Temperature Post-Vaccination 1
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Percentage of Participants With Elevated Temperature Post-Vaccination 12.00.03.08.1
SecondaryPercentage of Participants With Elevated Temperature Post-Vaccination 2

The participant's temperature was taken in the evening after Vaccination 2 and daily through Day 28, and was recorded on a VRC. An elevated temperature was defined as ≥39.0 °C (102.2 °F). The percentage of participants with elevated temperature after Vaccination 2 (up to approximately 28 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).

Time frame:
Up to 28 days post-Vaccination 2 (up to approximately 71 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Elevated Temperature Post-Vaccination 2
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Percentage of Participants With Elevated Temperature Post-Vaccination 20.00.0——
SecondaryPercentage of Participants With Varicella- and Herpes Zoster-Like Rashes Post-Vaccination 1

The development of varicella-like and herpes zoster-like rashes was recorded on a VRC. The percentage of participants who experienced varicella-like and herpes zoster-like rashes after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.

Time frame:
Up to approximately 42 days post-Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Varicella- and Herpes Zoster-Like Rashes Post-Vaccination 1
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Varicella-like rash6.00.06.12.7
Herpes zoster-like rash0.00.00.00.0
SecondaryPercentage of Participants With Varicella- and Herpes Zoster-Like Rashes Post-Vaccination 2

The development of varicella-like and herpes zoster-like rashes was recorded on a VRC. The percentage of participants who experienced varicella-like and herpes zoster-like rashes after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).

Time frame:
Up to approximately 42 days post-Vaccination 2 (up to approximately 86 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Varicella- and Herpes Zoster-Like Rashes Post-Vaccination 2
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Percentage of Participants With Varicella- and Herpes Zoster-Like Rashes Post-Vaccination 22.00.0——
SecondaryPercentage of Participants With Systemic AEs Post-Vaccination 1

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A systemic AE was defined as any non-injection-site AE. Systemic AEs were recorded on a VRC. The percentage of participants who experienced a systemic AE after Vaccination 1 (up to approximately 42 days post-vaccination) was summarized for all study arms.

Time frame:
Up to approximately 42 days post-Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic AEs Post-Vaccination 1
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Percentage of Participants With Systemic AEs Post-Vaccination 138.023.336.443.2
SecondaryPercentage of Participants With Systemic AEs Post-Vaccination 2

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A systemic AE was defined as any non-injection-site AE. Systemic AEs were recorded on a VRC. The percentage of participants who experienced a systemic AE after Vaccination 2 (up to approximately 42 days post-vaccination) was summarized for all study arms receiving a second vaccination (adults and adolescents).

Time frame:
Up to approximately 42 days post-Vaccination 2 (up to approximately 86 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic AEs Post-Vaccination 2
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Percentage of Participants With Systemic AEs Post-Vaccination 228.626.7——
SecondaryPercentage of Participants With 1 or More Serious Adverse Events (SAEs) Post-Vaccination 1 or Post-Vaccination 2

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event. The percentage of participants who experienced one or more SAEs after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.

Time frame:
Up to 42 days post-Vaccination 1 or post-Vaccination 2 (up to approximately 86 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With 1 or More Serious Adverse Events (SAEs) Post-Vaccination 1 or Post-Vaccination 2
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Percentage of Participants With 1 or More Serious Adverse Events (SAEs) Post-Vaccination 1 or Post-Vaccination 20.00.03.00.0
SecondaryPercentage of Participants With Vaccine-Related SAEs Post-Vaccination 1 or Post-Vaccination 2

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A vaccine-related SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event, that was considered at least possibly related to the study vaccine. The percentage of participants who experienced one or more vaccine-related SAEs after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.

Time frame:
Up to 42 days post-Vaccination 1 or post-Vaccination 2 (up to approximately 86 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Vaccine-Related SAEs Post-Vaccination 1 or Post-Vaccination 2
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Percentage of Participants With Vaccine-Related SAEs Post-Vaccination 1 or Post-Vaccination 20.00.00.00.0
SecondaryPercentage of Participants With Vaccine-Related Death Post-Vaccination 1 or Post-Vaccination 2

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A vaccine-related SAE was an AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or another important medical event, that was considered at least possibly related to the study vaccine. The percentage of participants who experienced a vaccine-related SAE that resulted in death after either vaccination (up to approximately 42 days post-vaccination) was summarized for all study arms.

Time frame:
Up to 42 days post-Vaccination 1 or post-Vaccination 2 (up to approximately 86 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Vaccine-Related Death Post-Vaccination 1 or Post-Vaccination 2
Percentage of participantsVARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of Age
Percentage of Participants With Vaccine-Related Death Post-Vaccination 1 or Post-Vaccination 20.00.00.00.0

Adverse events

Collected over Adverse Events: Up to 42 days post-Vaccination 1 or post-Vaccination 2 (up to approximately 86 days); All-Cause Mortality: Up to approximately 16 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VARIVAX Adults (18 to 75 Years)0/50 (0%)0/50 (0%)40/50 (80%)
VARIVAX Adolescents (13 to 17 Years)0/30 (0%)0/30 (0%)17/30 (56.7%)
VARIVAX Children (7 to 12 Years)0/33 (0%)1/33 (3%)15/33 (45.5%)
VARIVAX Children (12 Months to 6 Years)0/37 (0%)0/37 (0%)16/37 (43.2%)
Most frequent serious events
Most frequent serious events
EventVARIVAX Adults (18 to 75 Years)VARIVAX Adolescents (13 to 17 Years)VARIVAX Children (7 to 12 Years)VARIVAX Children (12 Months to 6 Years)
HeadacheNervous system disorders0/500/301/330/37
Most frequent other events
Showing 10 of 12
Most frequent other events
EventVARIVAX Adults (18 to 75 Years)VARIVAX Adolescents (13 to 17 Years)VARIVAX Children (7 to 12 Years)VARIVAX Children (12 Months to 6 Years)
Injection site painGeneral disorders29/5010/3010/335/37
Injection site erythemaGeneral disorders16/501/301/330/37
Body temperature increasedInvestigations6/505/302/339/37
HeadacheNervous system disorders9/506/305/330/37
Injection site swellingGeneral disorders7/501/301/330/37
Respiratory tract infectionInfections and infestations1/500/302/335/37
Respiratory tract infection viralInfections and infestations1/502/301/334/37
Rash vesicularSkin and subcutaneous tissue disorders3/500/302/331/37
DysmenorrhoeaReproductive system and breast disorders3/500/300/330/37
VomitingGastrointestinal disorders0/500/300/332/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)VARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of AgeTotal
Mean24.7 ± 6.015.1 ± 1.59.6 ± 1.63.2 ± 1.614.2 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)VARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of AgeTotal
Female3616141884
Male1414191966
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of AgeTotal
Hispanic or Latino10001
Not Hispanic or Latino48303337148
Unknown or Not Reported10001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of AgeTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White50303337150
More than one race00000
Unknown or Not Reported00000
Serostatus for Varicella-Zoster Virus (VZV)
Serostatus for Varicella-Zoster Virus (VZV)(Participants)VARIVAX Adults (18 to 75 Years)VARIVAX™ Adolescents 13 to 17 Years of AgeVARIVAX™ Children 7 to 12 Years of AgeVARIVAX™ Children 12 Months to 6 Years of AgeTotal
VZV Seronegative26182234100
VZV Seropositive241211350
08

Study locations

5 sites
  • Republican Clinical Infectious Hospital n.a. A.F. Agafonov ( Site 5816)
    Kazan, 420140, Russian Federation
  • Research Institute of Children Infections ( Site 5801)
    Saint Petersburg, 197022, Russian Federation
  • SPb Pasteur RI of Epidemiology and Microbiology ( Site 5817)
    Saint Petersburg, 197101, Russian Federation
  • Smolensk State Medical University ( Site 5814)
    Smolensk, 214019, Russian Federation
  • Smolensk State Medical University ( Site 5815)
    Smolensk, 214019, Russian Federation
09

References and documents

Publications

  • Paradis EM, Tikhonov O, Cao X, Kharit SM, Fokin A, Platt HL, Wittke F, Jotterand V. Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX) in healthy infants, children, and adolescents. Hum Vaccin Immunother. 2021 Nov 2;17(11):4183-4189. doi: 10.1080/21645515.2021.1975451. Epub 2021 Oct 26. PubMed 34702124 ↗
  • Paradis EM, Tikhonov O, Cao X, Kharit SM, Fokin A, Platt HL, Banniettis N. Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX) in healthy adults. Hum Vaccin Immunother. 2021 Nov 2;17(11):4177-4182. doi: 10.1080/21645515.2021.1957414. Epub 2021 Sep 2. PubMed 34473594 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jun 2020, 15 months.

Results were first posted in Apr 2021, 9 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Chickenpox, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 15. This study's 15 months is above that.

Counting every sponsor, half of 39 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2019
First posted
Feb 18, 2019
StartActual
Mar 1, 2019
Primary completionActual
Jun 19, 2020
CompletionActual
Jun 19, 2020
Results first posted
Apr 6, 2021
Last update
Apr 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03843632
Responsible party
Sponsor
First posted
Feb 18, 2019
Start date
Mar 1, 2019
Primary completion
Jun 19, 2020
Completion
Jun 19, 2020
Results posted
Apr 6, 2021
Last update
Apr 6, 2021

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion